Taho Pharmaceuticals has announced the submission of its new drug application (NDA) to the US Food and Drug Administration (FDA) for TAH3311, apixaban oral dissolving film (ODF).
TAH3311 is an innovative formulation designed to improve the delivery of apixaban, a widely used anticoagulant.
Developed on Taho’s proprietary transepithelial delivery system (TDS) platform, TAH3311 is formulated as an easy-to-use oral dissolving film (ODF). According to Taho, the patient-friendly format is particularly beneficial for stroke survivors, elderly patients, and others with swallowing difficulties, offering both greater convenience and improved treatment adherence. By eliminating the need for swallowing solid dosage forms, TAH3311 helps reduce the risk of choking and aspiration pneumonia.
“The NDA submission for TAH3311 reflects our unwavering commitment to addressing unmet patient needs through cutting-edge science,” said Lee, chief executive officer of Taho Pharmaceuticals. “We are proud to offer a patient-centred solution that has the potential to redefine the standard of care in anticoagulant therapy.”
Taho is actively seeking global partnership opportunities to accelerate the product’s time to market.
